Derm Cases · Dermatology / Endocrinology / Wound care
OSCE — yellow pretibial plaques: diagnose necrobiosis lipoidica and prevent ulceration
An 8-minute OSCE station on recognising classic pretibial necrobiosis lipoidica, diabetes association, biopsy indications, ulcer risk and stepwise medical/wound management including when to escalate.
On this page
Study tools
Target exams
NEET-PGINICETUSMLEPLABMRCP
Prompt
An 8-minute OSCE station on recognising classic pretibial necrobiosis lipoidica, diabetes association, biopsy indications, ulcer risk and stepwise medical/wound management including when to escalate.
Brief (to candidate)
A 42-year-old woman with longstanding type 1 diabetes has shiny yellow-brown pretibial plaques with telangiectasia and a violaceous rim; one plaque recently ulcerated after minor trauma. You have 8 minutes to diagnose necrobiosis lipoidica, organise metabolic assessment, and manage ulcer risk.
[3]Candidate instructions
- Give the classic morphology and site of NL.
- State the diabetes association and other differentials of pretibial plaques/ulcers.
- Indicate when to biopsy and expected histology concept (necrobiosis/granulomatous degeneration).
- Outline treatment ladder for non-ulcerated and ulcerated NL.
- Counsel on trauma avoidance and red flags (including rare SCC in chronic ulcer).
Examiner checklist (mark each domain / 10)
| Domain | Key actions expected |
|---|---|
| Clinical diagnosis | Yellow-brown, waxy/shiny, atrophic pretibial plaques with telangiectasia and violaceous active rim — NL until proven otherwise[1][8] |
| Association | Strong association with diabetes mellitus (type 1 classic) though NL can precede or occur without known DM — always assess glycaemic status and vascular risk[1] |
| Histology concept | Degeneration of dermal collagen (necrobiosis) with granulomatous inflammation; layered dermal involvement distinguishes from GA conceptually[2] |
| Biopsy triggers | Atypical site, lack of classic morphology, rapid growth, nodularity, disproportionate pain, suspicious ulcer edge, failure of expected course — exclude infection, other granulomatous disease, malignancy |
| Ulcer care | NL ulcers are common complication; protect from trauma, wound care, infection control; differentiate venous/arterial/neuropathic ulcers on legs[6] |
| Therapy | Potent topical/IL corticosteroids for active rim; calcineurin inhibitors, phototherapy, systemic agents (e.g. antimalarials, fumarates, biologics in refractory) per specialist/guideline pathways; optimise diabetes control as general health measure (skin response variable)[3] |
| Safety-net | Chronic non-healing ulcer edge → consider biopsy for SCC; multidisciplinary wound/endocrine input |
Model key actions
- Recognise classic pretibial NL morphology and link to diabetes screening/optimisation.[1][8]
- Prevent and manage ulceration with trauma avoidance and structured wound care.[6]
- Escalate atypical or refractory disease along guideline-informed pathways.[3]
Common errors
- Calling every pretibial rash NL without considering stasis dermatitis, GA, sarcoid, pretibial myxoedema.
- Aggressive debridement of inflammatory NL ulcers as if purely venous without diagnosis.
- Ignoring glycaemic assessment.
- Missing malignant change in chronic ulcerated plaques.
- Promising that tight HbA1c alone will reliably reverse established NL.
References5ShowHide
- [1]Lima AL, Illing T, Schliemann S, et al. Cutaneous Manifestations of Diabetes Mellitus: A Review. American Journal of Clinical Dermatology, 2017.PMID 28374407
- [2]Terziroli Beretta-Piccoli B, Mainetti C, Peeters MA, et al. Cutaneous Granulomatosis: a Comprehensive Review. Clinical Reviews in Allergy & Immunology, 2018.PMID 29352388
- [3]Erfurt-Berge C, Renner R, Peckruhn M, et al. S1-Guideline for diagnosis and therapy of necrobiosis lipoidica. Journal der Deutschen Dermatologischen Gesellschaft, 2026.PMID 41420334
- [6]Dissemond J, Placke JM, Moelleken M, et al. The Differential Diagnosis of Leg Ulcers. Deutsches Arzteblatt International, 2024.PMID 39115274
- [8]Liu MJ, Li J. Necrobiosis Lipoidica. The New England Journal of Medicine, 2024.PMID 38169491